TTrialPathMatch Me to Trials
← Back to trials
RecruitingHIV Infections

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52 weeks) of the treatment. The primary objective of this study are to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus switching to CAB and RPV in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.

Sponsor: Gilead Sciences

Where it's recruiting

California

Bakersfield · Beverly Hills · Hidden Valley Lake · Los Angeles …

Connecticut

New Haven

District of Columbia

Washington D.C.

Florida

DeLand · Fort Lauderdale · Ft. Pierce · Miami Gardens …

Georgia

Atlanta · Macon · Savannah

Illinois

Burr Ridge · Chicago

Michigan

Berkley

Missouri

Kansas City

New Mexico

Sante Fe

New York

The Bronx

North Carolina

Huntersville · Wilmington

Ohio

Cincinnati

Source: ClinicalTrials.gov · NCT07682961 · last updated 2026-11-19